Clinical Trials on Myelosuppression in United States

Total 4 results

Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy

Malignant Glioma | Myelosuppression

United States
Aileron Therapeutics, Inc.

Terminated

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Prevention of Chemotherapy-induced Myelosuppression

United States, Bosnia and Herzegovina, Serbia, Bulgaria
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)

Colorectal Cancer Metastatic | Chemotherapeutic Toxicity | Myelosuppression-Adult

China, Spain, United States, Hungary, United Kingdom, Poland, Ukraine, Italy
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)

Bladder Cancer | Urothelial Carcinoma | Chemotherapy-induced Neutropenia | Myelosuppression Adult | Metastatic Bladder Cancer

Hungary, Spain, United States, France, Georgia

3

Subscribe